On June 29th, Genomicare Biotechnology is pleased to announced it will be hosting an ISPOR webinar entitled “Real World Oncology in China: Unique Opportunities to Drive Improved Patient Access and Outcomes”.
GenomiCare Scientific Advisory Board Member Dr. Chen Lieping is elected by National Academy of Sciences as new member
GenomiCare is proud to announce On April 27, 2021, the National Academy of Sciences (NAS) announced the latest list of newly elected members, including Dr. Chen Lieping, a member of the GenomiCare Scientific Advisory Board (SAB).
The 2020 China Technology Fast 50 & China Rising Star lists were officially published by the Beijing office of Deloitte on December 9 and reported by dozens of news outlets. GenomiCare is on list of the 2020 China Rising Star thanks to its “two-wheel-drive” business model, powerful translational cancer research, and flexible data solutions for clinical oncology drug development.
GenomiCare is proud to announce that it has won the 2020 Leading Sci-Tech Innovation Company Award for its innovations in the R&D of cancer precision medicine, and that Dr. Xu Qiang, the company’s founder and CEO, has been named a 2020 Sci-Tech Innovation Leader.
GenomiCare, Inc. has recently reached a cooperation agreement with AWS on HIPAA compliance. This enables GenomiCare to store, process and utilize masked clinical data in a safer environment and therefore ensures the security and availability of personal health information (PHI) for our clients all over the world.
GenomiCare unveiled the results of PD-L1 immunohistochemistry images in outcome prediction at ASCO 2020
Recently, the summary of the results of GenomiCare PD-L1 immunohistochemistry (IHC) images in outcome prediction was included in the ASCO 2020 (56th Annual Meeting of the American Society of Clinical Oncology), entitled “Application of Automated Segmentation and Classification of PD-L1 Immunohistochemistry Images in Cancer Treatment Prediction”.